How do NAD+ precursors and senolytics fit into anti-aging therapeutics?

✓ Accepted answer

NAD+ precursors and senolytics represent two distinct but complementary pillars of modern anti-aging therapeutics, targeting cellular energy decline and cellular dysfunction, respectively.

• NAD+ Precursors: Compounds like nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are widely adopted in 2025 longevity protocols. They function by replenishing NAD+ levels, which naturally decline with age. This boost supports cellular respiration and DNA repair, addressing the energy crisis that often accompanies metabolic disorders.
• Senolytics: While NAD+ support focuses on function, senolytics focus on clearance. Agents such as dasatinib paired with quercetin, or the flavonoid fisetin, are used to identify and eliminate senescent cells. These 'zombie' cells secrete inflammatory factors that disrupt healthy tissue homeostasis, so their removal is a key intervention strategy.
• Integration Strategy: In 2025, expert consensus suggests using these therapies in alternating cycles. For instance, a regimen might involve daily NR supplementation for metabolic support combined with periodic, low-dose senolytic pulses every few weeks. This approach prevents the accumulation of damage while maintaining cellular energy efficiency.
• Regulatory Context: In the US and UK, these compounds are primarily available as research chemicals or dietary supplements. They are not FDA-approved drugs for aging itself. The US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) continue to monitor these compounds, with recent 2025 discussions focusing on standardizing dosage guidelines for safe use.

admin · 2026-10-09 14:39:54